Natural-cycle endometrial preparation for frozen embryo transfer holds up, and may be safer

IVF.net Newsdesk

26 January 2026

| | | |

Frozen embryo transfer now sits at the center of modern IVF, shaped by freeze-all strategies, single embryo transfer, and the growth of PGT cycles. As FET volumes have climbed, so has a practical and clinical question that many programs have learned to live with rather than resolve: should we prepare the endometrium by tracking a patient’s own ovulation, or by suppressing and replacing the cycle with exogenous estrogen and progesterone?

A new multicentre randomized clinical trial provides unusually strong footing for that decision. In ovulatory women planning frozen single blastocyst transfer, a natural ovulation regimen achieved healthy live birth rates that were statistically indistinguishable from a programmed hormone replacement regimen, while showing lower rates of several important maternal complications.

Study design in brief, with the details that matter clinically

The trial enrolled 4,376 ovulatory women aged 20–40 years across 24 academic fertility centres in China. Participants were randomized 1:1 to either a natural ovulation regimen or a programmed regimen for endometrial preparation. The natural arm relied on ultrasound monitoring of follicular development plus serial serum hormone measurements (luteinising hormone, oestradiol, progesterone) to time transfer, with a modified natural approach (hCG trigger) permitted when appropriate. The programmed arm used sequential exogenous oestrogen and progesterone to prepare the lining on a set schedule.

Importantly, this was not a small, single-center comparison powered only for pregnancy rates. The investigators prespecified dual primary outcomes: healthy live birth and pre-eclampsia or eclampsia following FET, with a broad set of secondary outcomes spanning cancellation, pregnancy milestones, pregnancy loss, and maternal, fetal, and neonatal complications.

Efficacy: similar healthy live birth rates in intention-to-treat analysis

The headline efficacy result is straightforward. In intention-to-treat analyses, 41.6% (910/2185) of patients in the natural ovulation arm achieved a healthy live birth, compared with 40.6% (890/2191) in the programmed arm (relative ratio 1.03; 95% CI 0.96 to 1.10; P=0.49). In other words, within the precision of this dataset, natural-cycle preparation performed as well as programmed hormone replacement in achieving the outcome patients care about most.

Safety: a consistent signal toward fewer maternal complications with natural ovulation

Where the trial becomes especially practice-shaping is maternal safety. Among patients who achieved clinical pregnancy, the risk of pre-eclampsia was lower in the natural ovulation arm: 2.9% (38/1302) versus 4.6% (61/1326), with a relative ratio of 0.63 (95% CI 0.43 to 0.94; P=0.02). No eclampsia was observed in either group.

Several other obstetric outcomes also favored the natural ovulation approach. The natural arm showed lower incidences of early pregnancy loss (12.1% vs 15.2%), placental accreta spectrum (1.8% vs 3.6%), caesarean section (69.5% vs 75.6%), and postpartum haemorrhage (2.0% vs 6.1%).

Neonatal outcomes, at least as captured here, did not differ meaningfully between groups. Birth weight and neonatal complication rates were similar, which is reassuring given the current reality that many programs default to programmed cycles for convenience and scheduling.

The trade-off: higher cancellation in the natural ovulation arm

Natural-cycle FET is rarely rejected because of concerns about implantation biology. More commonly, it is rejected because of operational fragility. The trial reflects that reality. Cycle cancellation was higher with natural ovulation: 16.2% (354/2185) versus 11.5% (251/2191), with cancellations in the natural arm mainly driven by absent or arrested follicle development.

This is the part that tends to shape lab and clinic sentiment. A higher cancellation rate means more monitoring, more uncertainty in thaw scheduling, and a greater chance of wasted preparation time for both patient and team. The key contribution of this trial is that it puts that inconvenience into a clearer risk-benefit frame: the convenience of a programmed regimen comes with a measurable increase in several maternal complications in this ovulatory population, even though the chance of a healthy live birth is similar.

Why might the presence of ovulation matter for maternal outcomes?

The trial itself is clinical rather than mechanistic, but it lands neatly on a biological hypothesis that has been building for years: the corpus luteum is not just a progesterone factory, and replacing progesterone does not necessarily replace luteal physiology.

In a programmed regimen, the endometrium can be rendered receptive, but the cycle may proceed without a functional corpus luteum. Observational work has linked programmed cycles to higher rates of hypertensive disorders of pregnancy, including pre-eclampsia, raising the possibility that vasoactive substances produced by the corpus luteum contribute to maternal vascular adaptation and placentation.

That hypothesis does not require a claim that programmed cycles are unsafe in all contexts. It suggests something narrower and more actionable: for people who can ovulate reliably, preserving ovulation and the luteal endocrine milieu may reduce downstream maternal risk, even when the embryo is thawed and transferred in a highly controlled lab environment.

How this shifts protocol conversations in real clinics

New Scientist framed the finding in the way many clinicians will instinctively interpret it: if outcomes are equivalent and maternal risks are lower, natural ovulation looks like the better default for ovulatory patients undergoing FET. BMJ’s own summary makes the same point while emphasizing the maternal complication profile.

In practice, “default” rarely means “only.” Programmed regimens remain essential for several common scenarios: irregular cycles, ovulatory dysfunction, donor or surrogate arrangements where scheduling constraints are significant, and situations where clinic operations make intensive monitoring impractical. The clinical value of this trial is that it strengthens the case for offering natural or modified natural approaches more proactively in people who are good candidates, rather than treating them as a boutique option for patients willing to accept more monitoring.

For lab teams, the implications are familiar but worth stating plainly. Natural and modified natural protocols push scheduling variability upstream into monitoring and trigger decisions, and downstream into thaw and transfer timing. That variability is manageable, but it benefits from strong internal coordination: clear cutoffs for LH surge interpretation, standardized trigger criteria when using hCG, and robust communication paths between clinic and lab so that warming plans track real-time endocrine and ultrasound findings.

For counselling, the framing becomes cleaner. Patients can be told that, in a large randomized dataset of ovulatory women undergoing frozen transfer, natural-cycle preparation achieved similar healthy live birth rates while lowering the risk of several maternal complications, at the cost of a higher chance that the cycle will be cancelled and need to be restarted.

Where this leaves the field

FET protocols have always been a blend of biology and logistics. The biology has been debated, but the logistics often decided the matter. This trial does not eliminate the logistical advantages of programmed cycles, and it does not claim that every patient should shift protocols. What it does is raise the evidentiary bar for treating convenience as neutral.

If you work in a setting where programmed cycles have become the unexamined norm for ovulatory patients, this is the kind of paper that justifies revisiting that norm, not because the old approach “fails,” but because equivalent efficacy combined with lower maternal complication rates is a rare and valuable combination in reproductive medicine.

Sources

23 January 2026. New Scientist